Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, randomised, double blind, placebo-controlled, dose-escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses and food effect of AK-119 administered orally to healthy volunteers

Next Previous
Trial Profile

A Phase I, randomised, double blind, placebo-controlled, dose-escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses and food effect of AK-119 administered orally to healthy volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs AK-119 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Akaal Pharma

    • Most Recent Events

    • 31 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top